Right to Access Innovation

Introduction

The right to access innovation refers to the legal and ethical principle that individuals and communities should be able to benefit from scientific, technological, and medical advancements. It emphasizes that innovation should not remain exclusively available to wealthy individuals or powerful corporations but should contribute to public welfare.

The concept is particularly important in biotechnology, pharmaceuticals, healthcare, artificial intelligence, and genetic engineering. Innovative technologies such as gene therapies, vaccines, diagnostic tools, and life-saving medicines can improve human health, but excessive costs, restrictive patents, and unequal distribution may prevent access.

The central legal debate concerns balancing intellectual property rights with public interest. Innovators require patent protection and financial incentives to support research and development. However, society also has an interest in ensuring that essential innovations remain accessible and affordable.

In India, the right to access innovation can be examined through Articles 14 and 21 of the Constitution, the Patents Act, 1970, and judicial decisions concerning access to medicines, compulsory licensing, and public health.

2. Case Laws

A. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court rejected Novartis's patent application for the beta-crystalline form of imatinib mesylate, a cancer medicine marketed as Glivec. The Court held that the drug did not satisfy the enhanced therapeutic efficacy requirement under Section 3(d) of the Patents Act, 1970.

The judgment explained that Section 3(d) seeks to prevent evergreening while preserving patent protection for genuine pharmaceutical innovations.

Global Health & Human Rights Database+1

Legal principle: Patent protection must encourage genuine innovation without unnecessarily restricting public access to essential medicines.

B. Bayer Corporation v. Union of India (2014) 60 PTC 277 (Bom)

The Bombay High Court upheld the compulsory licence granted to Natco Pharma for Bayer's cancer medicine Nexavar.

The Court considered the availability and affordability of the medicine and concluded that the statutory requirements for compulsory licensing were satisfied.

Global Health & Human Rights Database+1

Legal principle: Under Section 84 of the Patents Act, a compulsory licence may be granted when public requirements are unmet, the invention is unaffordable, or the statutory working requirement is not satisfied.

C. In Re: Distribution of Essential Supplies and Services During Pandemic (2021)

The Supreme Court considered the availability of essential medicines and vaccines during the COVID-19 pandemic.

The Court discussed the flexibility available under the TRIPS Agreement and the Doha Declaration to protect public health and promote access to medicines. It emphasized that compulsory licensing and other measures could be considered by the government.

Sci API+1

Legal principle: Intellectual property protection must be interpreted consistently with public-health objectives and access to essential innovations.

3. Legal Framework in India

Article 14: Protects against arbitrary discrimination in access to public services and government policies.

Article 21: Protects life and personal liberty and supports the constitutional importance of healthcare.

Section 84, Patents Act, 1970: Provides for compulsory licensing under specified circumstances.

Section 92, Patents Act, 1970: Provides special compulsory-licensing provisions in national emergencies, extreme urgency, or public non-commercial use.

Government of India

4. Major Legal Issues

Patent monopolies: Excessive exclusivity may restrict access to essential innovations.

Affordability: High prices may prevent economically disadvantaged individuals from benefiting from scientific progress.

Research incentives: Excessive restrictions on patents may reduce investment in research and development.

Technology transfer: Developing countries may require access to scientific knowledge and manufacturing capabilities.

Equality: Public policy should prevent innovation from becoming available only to privileged groups.

Conclusion

The right to access innovation represents an important balance between intellectual property protection and public welfare. Indian judicial decisions in Novartis, Bayer, and the COVID-19 essential-supplies proceedings demonstrate that patent rights are not absolute and may be subject to public-health considerations.

However, Indian law does not establish an unrestricted fundamental right to access every innovation. The legal framework instead promotes access through constitutional principles, patent limitations, compulsory licensing, and public-health policies.

The ultimate objective is to encourage genuine scientific innovation while ensuring that its benefits are accessible, affordable, and fairly distributed throughout society.